The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.

Top 5 Upgrades:

• Raymond James upgraded Disney (DIS) to Outperform from Market Perform with a $115 price target. The current macro backdrop and Disney’s international visitation headwinds provide an opportunity to invest at a “very attractive valuation,” the firm tells investors in a research note.

• DA Davidson upgraded Rivian (RIVN) to Neutral from Underperform with an unchanged price target of $14. The firm cites valuation for the upgrade following the stock’s recent selloff.

• Wolfe Research upgraded Edwards Lifesciences (EW) to Outperform from Peer Perform with a $92 price target. Checks suggest Medtronic’s (MDT) long-term Evolut TAVR data “flop” in February sets Edwards up for material share gain, the firm tells investors.

• Raymond James upgraded UnitedHealth (UNH) to Outperform from Market Perform with a $330 price target. The firm believes the company’s expense upside is greater than the Street expects following recent management comments

• HSBC upgraded Wells Fargo (WFC) to Buy from Hold with a price target of $94, down from $104. The firm says markets have “quickly repriced” higher downside macro risk and renewed credit concerns into the U.S. bank stocks. HSBC also upgraded Bank of America (BAC) to Buy from Hold.

Top 5 Downgrades:

• Goldman Sachs downgraded Nike (NKE) to Neutral from Buy with a price target of $52, down from $76. The firm left the company’s fiscal Q3 report “incrementally cautious” on the timeline of its recovery. JPMorgan and BofA also downgraded the shares to Neutral-equivalent ratings.

• Raymond James downgraded Apellis (APLS) to Market Perform from Outperform without a price target after the company entered into an agreement to be acquired by Biogen (BIIB) for $41.00 per share in cash at closing, or $5.6B. JPMorgan, Cantor Fitzgerald, Citi and Stifel also downgraded Apellis to Neutral-equivalent ratings.

• Citi downgraded PPG (PPG) to Neutral from Buy with a price target of $113, down from $132. The firm cites earnings headwinds and demand uncertainty for the downgrade of PPG.

• JPMorgan downgraded First Citizens (FCNCA) to Neutral from Overweight with a price target of $2,200, down from $2,450. The firm says a lack of interest rate cuts this year is the “exact opposite” to what First Citizens’ SVB franchise needs to show strong loan and deposit growth.

• Leerink downgraded Centessa (CNTA) to Market Perform from Outperform with a $40 price target after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per share in cash plus a non-transferable contingent value right worth up to $9 per share.